A Phase 4, 5-year, multicenter, prospective, observational, single-cohort study to document utilization, effectiveness and safety of daclizumab in subjects with relapsing forms of MS in clinical practice in Germany
Phase of Trial: Phase IV
Latest Information Update: 02 Mar 2018
At a glance
- Drugs Daclizumab (Primary)
- Indications Multiple sclerosis
- Focus Therapeutic Use
- Acronyms ZEUS
- Sponsors Biogen
- 02 Mar 2018 According to European Medicines Agency media release, the company has informed EMA of its decision to stop ongoing clinical studies with Zinbryta in the EU.
- 02 Mar 2018 Status changed from recruiting to discontinued, according to European Medicines Agency media release.
- 26 May 2017 New trial record